Companies
- Companies
- Company details
WILEX AG
Out-licensing
Phase III Clinical Development of REDECTANE® for the Diagnosis of Renal Cell Carcinoma More
Related Reports
Market Research Reports provided by reports.innovaro.com
Dec 2010 - 60 pages - $500
Nov 2010 - 76 pages - $600
Feb 2011 - 30 pages - $125
May 2011 - 36 pages - $125
Jul 2010 - 56 pages - $750
Mar 2011 - 60 pages - $250
Nov 2010 - 35 pages - $600
Jan 2010 - 70 pages - $2,000
Dec 2010 - 50 pages - $2,000
Nov 2010 - 65 pages - $2,000
Contact details
Thomas Borcholte
Head office
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us